Hemab Therapeutics Holdings, Inc. COAG
- Market cap
- $1.7B
- P/E
- 0.0×
Follow COAG
Target Price Range
Analyst price targets
Free account| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 23.00 |
Analyst estimates 2027–2029 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 55.42 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | — | Net Income | |||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
Hemab Therapeutics Holdings, Inc. (COAG) Latest News
24 Sep
Hemab Therapeutics announced the appointment of Keli Walbert to its board of directors, effective Sept. 24, 2026, with Walbert joining the Audit Committee after replacing Akshay Vaishnaw who remains on the board. Walbert brings more than 20 years of commercial leadership in biopharma, including roles at Horizon Therapeutics as Executive VP of U.S. Commercial, and prior positions at AbbVie, the American Medical Association, Abbott and UnitedHealthcare. She led launches of HUMIRA, TEPEZZA and DUOPA and has experience across sales, marketing, market access, patient services, advocacy and analytics. Hemab notes she will strengthen governance as the company advances its pipeline, which includes sutacimig (HMB-001) for Glanzmann thrombasthenia and Factor VII deficiency, HMB-002 for Von Willebrand Disease, and HMB-003 an antifibrinolytic for heavy menstrual bleeding. CEO Benny Sørensen and Chair John Maraganore praised her strategic fit and commercial expertise as Hemab moves toward later-stage development. Walbert's commercial leadership background could influence Hemab's go-to-market planning and timing of future launches, moderately impacting strategy and sentiment.
17 Sep
Hemab Therapeutics dosed the first participant in its Phase 1 trial of HMB-003 for heavy menstrual bleeding management. Phase 1 start marks standard early pipeline progress for the company's lead candidate.
21 Jul
Hemab Therapeutics Holdings, Inc. (COAG) IPO delivered 55% returns, outperforming AI listings in biotech sector gains. Strong 55% IPO return signals robust investor interest that can elevate stock performance and attract further capital.
14 Jul
Hemab Therapeutics presented clinical and preclinical data on Sutacimig for Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress. Conference data presentation may moderately raise pipeline visibility and investor interest without ensuring major commercial shifts.
12 Jul
Hemab Therapeutics presented new clinical data from HMB-002 in Von Willebrand Disease and introduced HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress. New clinical data presentation and pipeline expansion at major congress signals major strategic progress likely to shift company trajectory and investor sentiment.
26 Jun
Hemab Therapeutics to present clinical and preclinical data from multiple blood coagulation programs at the ISTH 2026 Congress. Announcing data presentations at a major congress may moderately influence Hemab's visibility and positioning in coagulation therapies.
8 Jun
Hemab Therapeutics outlines post-IPO pipeline progress and Sutacimig Phase III trial plans. Post-IPO pipeline push and Sutacimig Phase III plans signal major clinical and strategic advances that can shift company trajectory.
4 May
Hemab Therapeutics closed its upsized initial public offering with full exercise of the underwriters' option to purchase additional shares. The capital raised through the IPO strengthens financial resources and supports pipeline advancement.
3 May
Hemab Therapeutics Holdings, Inc. (COAG) launches IPO debut, placing focus on risks tied to COAG and its development pipeline. IPO debut with explicit focus on COAG and pipeline risks can significantly shift investor sentiment and valuation trajectory.
30 Apr
Hemab Therapeutics Holdings, Inc. priced its upsized initial public offering. Upsized IPO delivers major capital raise and public listing that alters financial position and investor access.